Abstract 3906
Background
Anti-HER2 agents were a breakthrough in the treatment of HER2-enriched breast cancer (BC). In this study, we aimed to describe the real-life efficacy and safety of pertuzumab-trastuzumab-taxane (PTT) combination in BC patients.
Methods
This study was conducted by the Turkish Oncology Group and reached 35 centers nationwide. 309 visceral metastatic, and trastuzumab naive patients who received first line PTT were included.
Results
Patients' characteristics and treatment details are summarized in the table. Median progression-free survival (PFS) was 28.5 months (95% CI:15.6-41.4), while median overall survival (OS) was 40.3 months (95%CI: 26.9-53.7). Brain metastatic patients (n = 13, 4.2%) had worse PFS (16.8m vs. 28.5m; HR:3.9, 95% CI:1.7-9.2, p = 0.002) and OS (26.7m vs. 40.3m; HR:3.2, 95% CI:1.3-7.6, p = 0.009). Elderly patients (>65y) had significantly lower OS results (19.8m vs. 40.3m; HR:0.4, %95 CI:0.2-0.8, p = 0.01). Docetaxel was the choice in 268 patients (86.7%), while 41 patients (13.3%) received paclitaxel. There was no statistically significant difference in PFS (28.5 m vs. 24.1 m; p = 0.61) and OS (40.3 m vs. NR; p = 0.17) between taxane groups. Additionally, ≥10 cycles of docetaxel were not associated with improvement in outcomes compared with 6-10 cycles. One treatment-related death due to sepsis was noted. In 8 patients (2.6%), 5-40% ejection fraction decrease from baseline was detected without any sign of heart failure.Table: 325P
Demographic characteristics and treatment details
| N = 309 | % | |
|---|---|---|
| Median age (year, range) | 51 (22-82) | |
| >65 years-old patients | 39 | 12.6 |
| De-novo metastatic patients | 258 | 83.5 |
| Histopathology | ||
| IDC | 290 | 93.9 |
| ILC | 3 | 1 |
| Mixt | 5 | 1.6 |
| Others | 11 | 3.5 |
| Hormone receptor status | ||
| ER and/or PR positive | 170 | 55.2 |
| ER/PR negative | 138 | 44.8 |
| Unknown | 1 | 0.3 |
| Metastatic site distribution | ||
| Liver ± LN/skeletal | 112 | 36.3 |
| Lung ± LN/skeletal | 120 | 38.8 |
| Brain only | 6 | 1.9 |
| Brain + liver + lung | 7 | 2.3 |
| Liver + lung | 16 | 5.2 |
| Other | 48 | 15.5 |
| Only skeletal or only LN | - | - |
| Prior therapies | ||
| Prior anthracyclines | 51 | 16.5 |
| Prior trastuzumab | NA | NA |
| Treatment details | ||
| Median number of cycle (range) | ||
| Pertuzumab-trastuzumab | 10 (1-75) | |
| Docetaxel | 6 (1-23) | |
| Paclitaxel | 3 (1- 26) |
IDC: Invasive Ductal Carcinoma ILC: Invasive lobular carcinoma LN: Lymph Node
Conclusions
This real-life practice population differs from the CLEOPATRA study in terms of visceral only metastatic disease, and inclusion of brain metastatic patients. Regardless of these negative prognostic characteristics, results are concordant with the pivotal study. Elderly patients had overall lower PFS, which necessitates further investigation of pertuzumab-trastuzumab combination with cytotoxic/antihormonal therapies. To our knowledge, this is the largest scale real-life clinical practice study of PTT to date.
Clinical trial identification
Legal entity responsible for the study
Ece ESIN, on behalf of Turkish Oncology Group.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4742 - Ki67 as an important predictor for Oncotype Dx Recurrence score risk groups in Early Breast cancer
Presenter: Fernando Namuche
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4697 - Genetic signatures always suggest undertreatment? Experience with PAM51
Presenter: Carolina Sales
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3158 - Significance of receptors expression, mitotic index and Ki67 in breast cancer patients with Nottingham Prognostic Index (NPI) poor prognosis score
Presenter: Mejri Nesrine
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3838 - Subgroup analyses of efficacy from a phase III study comparing SB3 (trastuzumab biosimilar) with reference trastuzumab in early breast cancer patients
Presenter: Javier Cortes Castan
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
715 - Autoimmunity and benefit from trastuzumab treatment in breast cancer: results from the HERA phase 3 trial
Presenter: Amir Sonnenblick
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2388 - Impact of hormone receptor status in HER2+ early breast cancer: a paradigm shift in the trastuzumab era
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3742 - Sefety profile of subcutaneous trastuzumab in patients with HER2-positive early breast cancer: The french HERMIONE non-interventional prospective study
Presenter: jean-philippe Jacquin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3647 - Real-life data on the cardiac toxicity of adjuvant fixed-dose subcutaneous trastuzumab in HER2-positive breast cancer.
Presenter: Rita De Sanctis
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3837 - Comprehensive evaluation of the pharmacokinetic profiles of SB3 and reference trastuzumab
Presenter: Xavier Pivot
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
1692 - The impact of neoadjuvant dual HER2 targeting with Pertuzumab and Trastuzumab on pathological complete response (pCR) rates: Kent Oncology Centre (KOC) experience
Presenter: Samantha Forner
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract